Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
IPS Research Company
mi
from
Oklahoma City, OK
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Suburban Research Associates
mi
from
Media, PA
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Suburban Research Associates
mi
from
Media, PA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
CNS Healthcare
mi
from
Memphis, TN
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
CNS Healthcare
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Nashville Neuroscience Group, PC
mi
from
Nashville, TN
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Nashville Neuroscience Group, PC
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Tekton Research
mi
from
Austin, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
DermResearch, Inc.
mi
from
Austin, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
DiscoveResearch, Inc.
mi
from
Bryan, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
DiscoveResearch, Inc.
mi
from
Bryan, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Synexus US, L.P. Formally known as Texas Pharmaceutical Research, LP, DBA Research Across America
mi
from
Dallas, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Synexus US, L.P. Formally known as Texas Pharmaceutical Research, LP, DBA Research Across America
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Central Texas Neurology Consultant
mi
from
Round Rock, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Central Texas Neurology Consultant
mi
from
Round Rock, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Radiant Research, San Antonio Center for Clinical Research
mi
from
San Antonio, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Radiant Research, San Antonio Center for Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Road Runner Research
mi
from
San Antonio, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Road Runner Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
ClinPoint Trials, LLC
mi
from
Waxahachie, TX
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
ClinPoint Trials, LLC
mi
from
Waxahachie, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
mi
from
West Jordan, UT
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
mi
from
West Jordan, UT
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Tidewater Integrated Medical Research
mi
from
Virginia Beach, VA
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Tidewater Integrated Medical Research
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Women's Clinical Research Center
mi
from
Seattle, WA
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Women's Clinical Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated:  12/31/1969
Kingfisher Cooperative
mi
from
Spokane, WA
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Status: Enrolling
Updated: 12/31/1969
Kingfisher Cooperative
mi
from
Spokane, WA
Click here to add this to my saved trials
MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine
MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine
Status: Enrolling
Updated:  12/31/1969
Kevin Hommel
mi
from
Cincinnati, OH
MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine
MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine
Status: Enrolling
Updated: 12/31/1969
Kevin Hommel
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine
Status: Enrolling
Updated:  12/31/1969
UCSF Headache Center
mi
from
San Francisco, CA
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine
Status: Enrolling
Updated: 12/31/1969
UCSF Headache Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine
Status: Enrolling
Updated:  12/31/1969
Montefiore Headache Center
mi
from
Bronx, NY
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine
Status: Enrolling
Updated: 12/31/1969
Montefiore Headache Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine
Status: Enrolling
Updated:  12/31/1969
New York Headache Center
mi
from
New York, NY
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine
Status: Enrolling
Updated: 12/31/1969
New York Headache Center
mi
from
New York, NY
Click here to add this to my saved trials
Metoclopramide for Post-Traumatic Headache. A Pilot Study
Metoclopramide for Post-Traumatic Headache. A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Metoclopramide for Post-Traumatic Headache. A Pilot Study
Metoclopramide for Post-Traumatic Headache. A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Baptist Health Center for Clinical Research
mi
from
Little Rock, AR
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Baptist Health Center for Clinical Research
mi
from
Little Rock, AR
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Encino, CA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
eStudySite
mi
from
La Mesa, CA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
eStudySite
mi
from
La Mesa, CA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Newport Beach, CA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Optimus Medical Group
mi
from
San Francisco, CA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Optimus Medical Group
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Ki Health Partners, LLC dba New England Institute for Clinical Research
mi
from
Stamford, CT
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Ki Health Partners, LLC dba New England Institute for Clinical Research
mi
from
Stamford, CT
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
MD Clinical
mi
from
Hallandale Beach, FL
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
AGA Clinical Trials
mi
from
Hialeah, FL
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
AGA Clinical Trials
mi
from
Hialeah, FL
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Multi-Specialty Research Associates, Inc
mi
from
Lake City, FL
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Multi-Specialty Research Associates, Inc
mi
from
Lake City, FL
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
QPS MRA
mi
from
Miami, FL
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
QPS MRA
mi
from
Miami, FL
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Ormond Medical Arts Pharmaceutical Research
mi
from
Ormond Beach, FL
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Ormond Medical Arts Pharmaceutical Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Synexus
mi
from
Atlanta, GA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Synexus
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
iResearch Atlanta LLC
mi
from
Decatur, GA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
iResearch Atlanta LLC
mi
from
Decatur, GA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Augusta, KA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Augusta, KA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Cresent City Headache and Neurology Center LLC
mi
from
Chalmette, LA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Cresent City Headache and Neurology Center LLC
mi
from
Chalmette, LA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
DelRicht Research
mi
from
New Orleans, LA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
DelRicht Research
mi
from
New Orleans, LA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Community Clinical Research Network/Milford Emergency Associates, Inc
mi
from
Marlborough, MA
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Community Clinical Research Network/Milford Emergency Associates, Inc
mi
from
Marlborough, MA
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Institute Inc.
mi
from
Minneapolis, MN
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Institute Inc.
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Institute Inc
mi
from
Plymouth, MN
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Institute Inc
mi
from
Plymouth, MN
Click here to add this to my saved trials